Short Interest in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Rises By 21.5%

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) was the recipient of a large increase in short interest in January. As of January 30th, there was short interest totaling 1,983,177 shares, an increase of 21.5% from the January 15th total of 1,632,436 shares. Based on an average daily trading volume, of 2,033,323 shares, the days-to-cover ratio is presently 1.0 days. Currently, 7.9% of the shares of the company are short sold. Currently, 7.9% of the shares of the company are short sold. Based on an average daily trading volume, of 2,033,323 shares, the days-to-cover ratio is presently 1.0 days.

Insiders Place Their Bets

In other MAIA Biotechnology news, Director Ngar Yee Louie bought 81,699 shares of the business’s stock in a transaction dated Monday, December 22nd. The shares were purchased at an average price of $1.22 per share, for a total transaction of $99,672.78. Following the purchase, the director directly owned 1,248,888 shares of the company’s stock, valued at approximately $1,523,643.36. This represents a 7.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Vlad Vitoc acquired 50,000 shares of the firm’s stock in a transaction that occurred on Friday, November 28th. The stock was purchased at an average cost of $1.14 per share, with a total value of $57,000.00. Following the acquisition, the chief executive officer owned 881,421 shares in the company, valued at $1,004,819.94. The trade was a 6.01% increase in their position. The SEC filing for this purchase provides additional information. Insiders have bought 349,122 shares of company stock worth $402,193 over the last 90 days. 32.32% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of MAIA. Centric Wealth Management grew its position in shares of MAIA Biotechnology by 2.0% during the 4th quarter. Centric Wealth Management now owns 586,398 shares of the company’s stock valued at $897,000 after purchasing an additional 11,500 shares in the last quarter. Geode Capital Management LLC grew its position in MAIA Biotechnology by 9.5% during the fourth quarter. Geode Capital Management LLC now owns 296,740 shares of the company’s stock worth $454,000 after buying an additional 25,684 shares in the last quarter. Jane Street Group LLC bought a new position in MAIA Biotechnology in the 4th quarter worth about $120,000. Ritholtz Wealth Management purchased a new stake in shares of MAIA Biotechnology in the 4th quarter valued at about $35,000. Finally, Marshall Wace LLP bought a new stake in shares of MAIA Biotechnology during the 2nd quarter valued at about $29,000. 5.65% of the stock is owned by institutional investors.

MAIA Biotechnology Stock Up 5.6%

MAIA stock opened at $2.08 on Thursday. The stock has a 50-day simple moving average of $1.79 and a two-hundred day simple moving average of $1.54. MAIA Biotechnology has a twelve month low of $0.87 and a twelve month high of $3.19. The firm has a market capitalization of $77.02 million, a PE ratio of -2.85 and a beta of -0.06.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.